Principal Investigator
Coral Olazagasti
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240092
Clinical Trial Summary
Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants with MAGE-A4 Expressing Solid Tumors
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Thoracic Oncology
Contact Information
Phone Number
305-243-2647